Fosamax and Osteonecrosis of the Jaw: Causation and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information has long emphasized the importance of understanding how systemic factors influence localized conditions. In this tradition, public health discourse has consistently highlighted the need to recognize that medications intended for broad therapeutic benefit can, under certain circumstances, contribute to adverse outcomes in specific tissues. This foundational perspective has guided clinicians and researchers in identifying unexpected correlations between widely prescribed treatments and rare but serious complications. Within this framework, the relationship between bisphosphonate therapy and skeletal health has been a subject of sustained inquiry, reflecting a commitment to refining risk-benefit assessments in routine medical practice.

Transition from General Principles to Occupational Exposure Concerns

As this heritage of inquiry evolves, attention naturally shifts from general population-level considerations to more focused occupational exposure concerns. Specifically, the transition involves examining how prolonged or high-dose exposure to agents like Fosamax, particularly in contexts where cumulative exposure is elevated, may heighten the risk of osteonecrosis of the jaw. This pivot underscores a broader principle: that the same mechanisms underlying therapeutic efficacy can, under altered exposure conditions, pose distinct hazards. Thus, the occupational exposure concern emerges as a logical extension of the legacy heritage, applying its lessons to settings where exposure intensity and duration differ markedly from standard therapeutic use.

Pharmacology and Approved Uses of Fosamax

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Osteonecrosis of the Jaw: Clinical Presentation and Diagnosis

A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis is typically based on clinical examination and imaging, with the presence of exposed bone persisting for more than eight weeks in the absence of radiation therapy. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma. Multiscale characterization of jawbone tissue has provided comprehensive information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, the jawbone's unique environment, with its thin mucosal covering and frequent exposure to oral bacteria, may predispose it to necrosis when remodeling is suppressed.

Risk Factors and Duration of Exposure

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on ONJ under Warnings and Precautions (5.4). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for osteoporosis treatment, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Epidemiological Evidence

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some individuals. The timeline between exposure and documented harm is further characterized by epidemiological data. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk remains small, and the risk decreases after stopping the medication.

Summary and Clinical Implications

In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of additional risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, but the absolute risk is low. Patients and healthcare providers should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, especially when considering long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication that inhibits bone resorption, increasing bone mass and reducing fracture risk. It is approved for osteoporosis and Paget's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition of exposed necrotic bone in the jaw, often after dental procedures, diagnosed by clinical exam and imaging showing exposed bone for >8 weeks without radiation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, and longer duration of Fosamax use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the duration of Fosamax use affect ONJ risk?

Longer use increases risk: ONJ risk is threefold higher after 2-3 years and eightfold higher after 10 years compared to past use, though absolute risk remains low (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What does the Fosamax label say about ONJ?

The label includes a warning about ONJ, lists risk factors, and advises that discontinuation may reduce risk for those needing dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.